Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib effects on bone turnover in relapsed multiple myeloma
NL-OMON32496Not yet recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Aug 2008
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Vrije University Medical Center. Primary endpoints: Accuracy of [18F]PET/CT for bone turnover assessment and Change in bone turnover before and after bortezomib treatment. Planned start Aug 2008; status: not yet recruiting.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON32496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32496.